Patients must have pathologically/histologically confirmed tumor of non-small cell histology
Predominant non-squamous histology (patients with NSCLC not otherwise specified [NOS] are eligible); mixed tumors will be categorized by the predominant cell type; if small cell elements are present the patient is ineligible
Pure small cell or other variant (non-adenocarcinoma) prostate cancer histology for which treatment with abiraterone would not be considered appropriate
Patient must have epithelioid or biphasic histology (sarcomatoid histology is excluded); histologic diagnosis and typing of mesothelioma will require at least a core needle biopsy or surgical biopsy of the pleura via thoracoscopy and small thoracotomy; cytology only will not be regarded as sufficient for the diagnosis
Patients with histology consistent with pure SCU must have positive INI1/SMARCB1 staining
Have documented histologically or cytologically confirmed advanced NSCLC with no small cell histology or neuroendocrine histology
Malignancy of squamous histology. In cases of mixed histology, squamous must be the predominant histology.
Must have histologic demonstration of metastatic or surgically unresectable urothelial cancer. Minor components of variant histology such as glandular or squamous differentiation, or evolution to more aggressive phenotypes such as sarcomatoid or micropapillary change are acceptable
Histology other than adenocarcinoma
Mucinous or tubal histology or other good prognosis histology
Intrahepatic cholangiocarcinoma diagnosed by histology.
Has non-squamous histology NSCLC.
Patient has disease of nasopharyngeal carcinoma histology
Mixed histology including clear cell, serous, undifferentiated or sarcomatous elements
For phase 1, patients with multifocal low-grade Ta histology will be eligible for participation
For phase 2, individuals with Ta disease only must have documentation of high-grade histology
Patients may not have metastatic disease, unless aged 2-10 with embryonal histology
Ovarian cancer cohort only: Subjects must have high-grade non-mucinous histology (carcinosarcomas are allowed).
Non-clear cell histology
Subjects with poorly differentiated or small cell carcinoma histology
STUDY TREATMENT: Histology consistent with high-grade epithelial ovarian cancer (excluding mucinous carcinoma, clear cell carcinoma, and carcinosarcoma).
GENERAL: Mucinous, low-grade histology, clear cell carcinoma, or carcinosarcoma.
Histologic demonstration of transitional cell carcinoma of the urothelium. Minor components ( less than [<] 50 percent [%] overall) of variant histology such as glandular or squamous differentiation, or evolution to more aggressive phenotypes such as sarcomatoid or micropapillary change are acceptable
Histologically confirmed prostate cancer (mixed histology is acceptable, with the exception of the small cell pure phenotype, which is be excluded)
Patients must have histologic or cytological diagnosis of advanced/metastatic NSCLC with no curative treatment options; for those with mixed histology, there must be a predominant histology
Pathologic confirmation of eligible histology
Mixed small-cell lung cancer and sarcomatoid variant NSCLC histology
Has any evidence of small cell histology, or combined small cell and non-small cell histology, in original tumor biopsy or in screening biopsy performed since progression.
Histology other than squamous cell carcinoma
Able to understand their disease and the exploratory nature of combining surgery and HIPEC for this histology
Patients with multiple primary lung tumors (defined below) are eligible:\r\n* Synchronous tumors (diagnosed within 6 months [mo]),\r\n** Different histology, \r\n** Same histology,\r\n** Second tumor in different lobed or lung;\r\n* Metachronous tumors (diagnosed > 6 mo apart),\r\n** Different histology,\r\n** Same histology,\r\n** Second tumor in different lobe or lung,\r\n** Tumor-free interval of at least 4 years (y)
Internal review of histology
Patients with a histology of lymphoma and myeloma histologies
Histologically confirmed mPAC (mixed histology is acceptable as long as the predominant histology is pancreatic adenocarcinoma)
Histologically confirmed prostate cancer (mixed histology is acceptable, with the exception of the small cell pure phenotype, which is be excluded
Histology showing mucinous or low-grade epithelial ovarian carcinoma
Known (histology/cytology proven) or evidenced by radiology of recurrent and/or metastatic SCCHN not suited for local therapy
Craniopharyngioma diagnosed by histology, cytology or neuroimaging or intra-operative assessment
Histology showing mucinous or low grade epithelial carcinoma
Any component of small cell histology
Internal review of histology
Patients with lung cancer with squamous histology
Patients with squamous cell histology or non-squamous cell histology previously treated by pemetrexed and with a contraindication for docetaxel with grade ? 2 neuropathy or hypersensitivity reaction to medications formulated with polysorbate 80 (Tween 80) as they could be randomly assigned to Arm B.
Biopsy confirmed CD8+ CTCL histology
Patients with non-clear cell histology must have received at least one prior anti-cancer therapy; prior rapalogues are allowed
Histologically-confirmed diagnosis of high risk non-muscle-invasive (T1, high grade Ta and / or carcinoma in situ [CIS]) transitional cell carcinoma of the bladder (mixed histology tumors allowed if transitional cell histology is predominant histology).
Patients with positive pelvic washings as the only extra-uterine disease are NOT eligible if the histology is other than clear cell or papillary serous carcinoma.
Small cell or other variant (non-adenocarcinoma) prostate cancer histology, unless there is evidence that the tumor expresses PAP
Melanoma or renal histology
All patients must have histologic demonstration of metastatic or locally unresectable transitional cell carcinoma of the urothelium; variant histology is allowed as long as there is an urothelial component present; the principal investigator (PI), will serve as the final arbiter of eligibility
Patients must have histologic or cytologic diagnosis of advanced/metastatic NSCLC. For those with mixed histology, there must be a predominant histology.
Glandular abnormalities on cytology or histology
Patients with gynecologic malignancy of low-grade serous or borderline histology
Histologic examination showing invasive lobular histology.
Bulky celiac adenopathy (?2.5 cm) or nonadenocarcinoma histology.
Presence of measurable disease that has been confirmed by histology or cytology.
Participants must have classical histology posterior fossa medulloblastoma as determined by institutional neuro-pathological evaluation
Epithelioid or biphasic histology subtype (Note: patients with biphasic histology can have < 10% sarcomatoid)
> 10% Sarcomatoid or desmoplastic histology
Patients with biopsy-proven small cell or sarcomatoid histology
Radiation sensitive histology such as lymphoma, myeloma, or plasmacytoma are not allowed
Since small cell tumors of the bladder are often associated with other variant histology including TCC and adenocarcinoma, the presence of variant histology will be allowed
Histologic demonstration of transitional cell carcinoma of the urothelium. Minor components (less than [<] 50 percent [%] overall) of variant histology such as glandular or squamous differentiation, or evolution to more aggressive phenotypes such as sarcomatoid or micropapillary change are acceptable
Patients must have histologically confirmed disease that is unresectable and not amenable to curative intent therapy: \r\n* Cohort A: salivary gland cancers (mucoepidermoid carcinoma, adenocarcinoma, adenoidcystic carcinoma, acinic cell carcinoma, or other histology) originating in salivary glands \r\n* Cohort B: thyroid cancer, radioactive iodine (RAI)-refractory and after failure, intolerance to or refusal of anti-antiangiogenic therapy, or with evidence of dedifferentiated or anaplastic histology
For Stage 2 only, mixed histology i.e. patients with >10% non-endometrioid malignant cells in provided histopathology samples.
Predominantly squamous cell histology NSCLC. Mixed tumors will be categorized by the predominant cell type; if small cell elements are present, the participant is ineligible.
Non-adenocarcinoma histology
The invasive component of the tumor has a grade 3 histology
Patients with small cell lung cancer (SCLC) documented by histology or cytology from brushing, washing, or needle aspiration of a defined lesion, but not from sputum cytology alone
Subjects with any kind of non-small cell lung carcinoma (NSCLC) histology documented by histology or cytology from bronchial brushing or washing, or needle aspiration of a defined lesion but not from sputum cytology alone
Histology other than adenocarcinoma
Able to understand their disease and the exploratory nature of combining surgery and HIPEC for this histology
Presence of lymphovascular invasion and/micropapillary disease as shown in the histology of the biopsy sample
Must have received at least 2 prior lines of therapy for the treatment of current histology; there are no treatment options available known to provide clinical benefit. Refer to National Comprehensive Cancer Network (NCCN) guidelines of each respective histology for guidance.
Carcinomas of the nasopharynx, salivary gland, or nonsquamous cell histology are excluded.
Has predominantly squamous cell histology NSCLC.
Evidence of signet ring involvement on histology
Diagnosis of ovarian carcinoma with mucinous histology
Diagnosis with confirmed histology of one or more of the following:
Histologically-confirmed inoperable superior, medial, or distal third esophageal adenocarcinoma (Siewert type I classification may be included, provided there is no mixed histology)
Patients with predominant (> 30%) non-endometrioid histology (such as serous, clear cell, or carcinosarcoma)
Tumors of adenocarcinoma, melanoma, small cell and basal cell histology are excluded
Small cell or other (non-adenocarcinoma) variant prostate cancer histology
The patient must have a pathologically confirmed (by histology or cytology) diagnosis of SCLC, which is currently extensive disease.
Patients with grade 2-3 endometrioid, uterine serous, clear cell, mucinous, squamous, transitional cell, sarcomas, or carcinosarcoma histology
Poorly differentiated histology, uterine papillary serous carcinoma, clear cell carcinoma or carcinosarcoma is acceptable as long as the predominant metastatic component is epithelial (versus sarcomatous)
Any bladder tumor with histology other than TCC.
Metastatic or recurrent merkel cell carcinoma (MCC) confirmed by histology
Patients with a small cell component in their histology are excluded
Evidence of histology of the tumor other than papillary serous adenocarcinoma or endometrioid type of endometrial carcinoma or mixed histology of the tumor;
Non-squamous histology including lymphoma, neuroendocrine carcinoma, adenocarcinoma, or other histology
Histology other than squamous cell carcinoma
Patients with a diagnosis of intrathoracic lung carcinoma of squamous cell histology are not eligible for participation
Histologic or cytologic diagnosis of SCLC (Note: patients with mixed histology are not eligible)
Adenocarcinoma histology (including poorly differentiated non-small cell lung cancer [NSCLC], favor adenocarcinoma) of any variant, including adenosquamous histology
Non-clear cell or predominantly (> 50%) sarcomatoid histology
Patients who have uterine sarcomas, carcinosarcomas, any serous histology or pure clear cell carcinomas
Small cell or other variant prostate cancer histology
Craniopharyngioma diagnosed by histology, cytology or neuroimaging
Small cell or other variant prostate cancer histology
COHORT 2 ONLY: Patients must have pathologically or cytologically confirmed salivary gland cancer of any histology except for adenoid cystic carcinoma
Grade 3 histology
Mucinous or tubal histology or other good prognosis histology
Histology other than squamous cell carcinoma
Medulloblastoma patients who are >= 3 and < 5 years of age with no more than 1cm^2 of residual tumor and with no evidence of CNS metastasis; medulloblastoma patients in the >= 3 and < 5 years old age group with anaplastic histology, large cell histology, melanotic differentiation, or myogenic differentiation or tumors with MYC or MYCN gain or amplification are excluded; pathology from collaborating institutions’ patients must be centrally reviewed prior to enrollment for confirmation
Subject has histologically confirmed locally advanced, metastatic or unresectable Stage IIIB/IV adenocarcinoma NSCLC (newly diagnosed or recurrent). Subjects with mixed histology are eligible if adenocarcinoma is the predominant histology.
Patient must have a histological diagnosis of neuroblastoma or ganglioneuroblastoma and be either newly diagnosed with high risk disease or have failed previous treatment:\r\n* Patients who have failed previous treatment may have had no more than one earlier autologous hematopoietic progenitor cell (HPC) transplant\r\n* High risk is defined as any of the following scenarios:\r\n** Stage 2A/2B, any age , amplified myelocytomatosis viral related oncogene, neuroblastoma derived (avian) (MYCN) , any ploidy , any International Neuroblastoma Pathology Classification (INPC) histology\r\n** Stage 3, any age , amplified MYCN , any ploidy, any INPA histology\r\n** Stage 3, age >= 547 days , not amplified MYCN, any ploidy , unfavorable INPA histology\r\n** Stage 4, age < 365 days , amplified MYCN, any ploidy, any INPA histology \r\n** Stage 4, age 365 - < 547 days , amplified MYCN, any ploidy , any INPA histology\r\n** Stage 4, age 365 - < 547 days , any MYCN , ploidy (DI) = 1, any INPA histology\r\n** Stage 4, age 365 - < 547 days , any MYCN, any ploidy, unfavorable INPA histology\r\n** Stage 4, age >= 547 days , any MYCN, any ploidy, any INPA histology\r\n** Stage 4S , age < 365 days , amplified MYCN, any ploidy, any INPA histology
Diagnosis of metastatic lung cancer, with histologic confirmation of the primary NSCLC histology and with at least one lesion amenable for intra-tumoral injection of MV-NIS.
Patients with mixed histology SCLC and NSCLC are permitted
Sarcomatoid histology
Patients with non-squamous cell histology
Histology grades 1, 2 or 3a
Squamous or mixed histology (eg, adenosquamous) NSCLC
Pancreatic tumor histology other than carcinoma (e.g. islet cell, lymphoma, etc.)
Patients with unknown status of EGFR mutation (only for patients with adenocarcinoma histology)
Mixed histology or undifferentiated small cell carcinoma, any stage
Malignant germ cell tumors with mixed histology such as embryonal carcinoma, choriocarcinoma, yolk sac tumor or seminoma. Note - this refers to the histology at the time of enrollment, not the histolgy at the time of initial presentation.
Mixed small cell and NSCLC histology
Positive for KRAS mutation or Squamous cell histology
Subjects with NSCLC of predominantly squamous histology documented by histology or cytology from brushing, washing or needle aspiration of a defined lesion but not from sputum cytology alone
Mixed tumor histology
Tumors with non-clear cell histology must be ectonucleotide pyrophosphatase/phosphodiesterase family member 3 (ENPP3) positive at pre-screening. This sub-group does not have any prior therapy requirement.
Tumors with clear cell histology: subject must have progressed after at least one anti-VEGFR therapy
Tumors with papillary histology: includes unclassified histology with papillary features and must be ENPP3 positive at pre-screening. This sub-group does not have any prior therapy requirement.
Tumors with squamous cell histology
Patients with one of the following diagnoses by histological diagnoses and by head and spine magnetic resonance imaging (MRI):\r\n* Classic histology metastatic medulloblastoma\r\n* Desmoplastic histology metastatic medulloblastoma\r\n* High-risk supratentorial, non-metastatic, PNET\r\n* Metastatic PNET
Anaplastic histology will be excluded
Participants who have squamous histology.
No collecting duct, medullary or sarcomatoid histology.
predominant clear cell histology
Mixed histology of the tumor or evidence of tumor histology other than serous carcinoma or endometrioid type of endometrial carcinoma;
Documented pancreas cancer by cytology, or histology
Radiosensitive histology with planned RT dose less than 50 gray.
Histology showing mucinous or low grade epithelial ovarian carcinoma
Completely resected NSCLC with negative margins (R0); cancers with a histology of “adenosquamous” are considered a type of adenocarcinoma and thus a “nonsquamous” histology; patients with squamous cell carcinoma are eligible only if the registering site has EA5142 IRB approved
Multiple prior breast biopsies regardless of histology
Diagnosis must be documented by histology or cytology from brushings, washings, or needle aspiration of a defined lesion but not from sputum cytology
Histology other than adenocarcinoma
Has any evidence of small cell histology, or combined small cell and non-small cell histology, in original tumor biopsy or in Screening biopsy performed after progression
Histological diagnosis other than PTC; patients with anaplastic tumors are not eligible; however, patients whose tumors contain areas of un-differentiated or dedifferentiated histology may enroll provided the original diagnosis was clearly PTC, and the tumor histology remains predominantly papillary at enrollment
Have variant histology (micropapillary, nested variant, non-urothelial cell carcinoma elements)
Cancer Registry cases include stage I-III colon cancer (adenocarcinoma histology), stage I-III rectal cancer (adenocarcinoma histology), stage I-III non-small cell lung cancer (squamous or adenocarcinoma histology)
Predominant clear cell histology:
Participants must possess at least two of the following clinical characteristics which enrich for EGFR mutations:\r\n* Smoked less than 10 pack years\r\n* Asian race\r\n* Adenocarcinoma (including adenosquamous carcinoma) on histology or cytology
